Cronos Group Inc vs Symbotic Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Symbotic Inc trades at $42.39 (market cap $5.46B). The key difference: Symbotic Inc is far larger — about 4.6× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Symbotic Inc for 23 Days on average.
| CRON | SYM | |
|---|---|---|
Market Cap | $1.18B | $5.46B |
Volume | 968,037 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $3.55 | $87.30 |
52-Week Low | $2.30 | $38.22 |
Typical Hold Time | 22 Days | 23 Days |
Enterprise Value | $387.62M | $3.72B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% today amid a bearish technical signal. Recent quarterly earnings show beats in Q1 and Q2 2026, with revenue growth from $118M in 2024 to $147M in 2025. The company reported a net loss of $9.45M in 2025 but projects a profit of $70M for 2026. Analyst sentiment is mixed with a 20% buy rating. News highlights focus on international expansion and a recent Investor Day outlining growth strategies.
Outlook is cautiously optimistic given projected profitability in 2026 and strong cash reserves, but risks include sustained negative cash flow and competitive pressures. The stock's valuation metrics like P/E of 16.95 and P/S of 6.84 suggest moderate pricing relative to peers, though high EV/EBITDA of 43 indicates premium expectations.
SYM trades at $42.73, down 1.34% today, with bearish technical signals dominating. The stock shows mixed fundamentals with strong revenue growth projected ($2.6B in 2026) but negative 2025 net income of -$16.94M. Recent earnings show two misses against expectations, though Q4 2025 beat estimates. Analyst consensus remains positive with 61% buy ratings and a $60.33 price target, representing 41% upside potential from current levels.
The outlook balances growth potential against execution risks. SYM's $22.5B backlog and expanding AI/robotics market position offer substantial upside, but customer concentration (85% Walmart revenue) and recent earnings misses create near-term uncertainty. Technical indicators suggest caution with bearish moving average signals, though oversold conditions may present entry opportunities for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →